Levofolene (Levoleucovorin)

Levoleucovorin is a reduced form of folic acid that bypasses the blockade of dihydrofolate reductase caused by drugs like methotrexate. It enters cells as 5‑methyltetrahydrofolate, providing methyl groups needed for thymidylate and purine production, thereby allowing DNA replication and repair to continue despite antifolate exposure.

The dose of Levofolene is individualized and determined by the prescribing clinician based on the specific indication, patient weight, renal function, and the concurrent methotrexate regimen. Healthcare providers calculate the appropriate amount to achieve effective folate rescue while minimizing adverse effects.

Safety data for Levofolene in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case carefully and discuss potential risks with the patient.

To order Levofolene, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and assistance with import documentation.

Levofolene (levoleucovorin) is a reduced folate that offers rapid intracellular conversion to active tetrahydrofolate, often providing more efficient rescue than folic acid itself. Compared with calcium folinate, it has similar efficacy but may be preferred in settings requiring sterile injectable formulations and precise dosing for high‑dose methotrexate protocols.

Levofolene should be stored at 2‑8 °C, protected from light, and kept in its original packaging to maintain stability. It must not be frozen or shaken vigorously. If the product is supplied as a lyophilised powder, reconstitute with the recommended diluent immediately before use and discard any unused portion after the specified time.

Levofolene is administered by intramuscular or intravenous injection, depending on the clinical protocol. The route, rate of infusion, and timing relative to methotrexate administration are determined by the treating physician to ensure optimal folate rescue and minimize toxicity.

Serious adverse events include anaphylactic reactions, acute renal failure, and severe hepatic toxicity. Patients should be monitored for signs of hypersensitivity, sudden changes in kidney function, or marked elevations in liver enzymes, and treatment should be discontinued promptly if any of these occur.

Levofolene is contraindicated in individuals with known hypersensitivity to levoleucovorin or any component of the formulation. Caution is also advised for patients with severe renal or hepatic impairment, as well as for those receiving overlapping antifolate therapies without appropriate monitoring.